News / Press
Contact
Who We Are
Vision
ESG Philosophy
Leadership
Board of Directors
Scientific Advisors
Strategic Collaborations
Our Approach to Clinical Trials
Our Focus
Plaque Psoriasis
Atopic Dermatitis
Seborrheic Dermatitis
Scalp Psoriasis
Hand Eczema
Vitiligo
Alopecia Areata
Pipeline
Topical Roflumilast Cream (ARQ-151)
Topical Roflumilast Foam (ARQ-154)
ARQ-252
ARQ-255
Clinical Programs
Clinical Trials
Scientific Publications
Media
Investors
Healthcare Professionals
Medical Affairs
Media
Arcutis Media Resources
Arcutis Media Resources
Roflumilast Foam: Phase 2 Trial for the Treatment of Seborrheic Dermatitis
The Impact of Seborrheic Dermatitis
New England Journal of Medicine, Infographic / Backgrounder, July 2020
